ASCL1 has been found to be associated with lack of EGFR mutations, PD-L1 negative expression, and a poor immune cell infiltration in adenocarcinomas with neuroendocrine differentiation [26], but not to characterize subsets of SCLC with a distinctive clinical outcome. The gene discussed is ASCL1; the disease is adenocarcinoma.